Virology Publishes Genocea Biosciences HSV-2 Antigen Discovery Paper

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it’s ATLAS™ platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program. The paper, titled “Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors,” positively identified multiple viral antigens that are associated with naturally-induced protective CD4+ and CD8+ T cell responses, presenting possible targets for the development of new immunotherapies and prophylactic vaccines.

Help employers find you! Check out all the jobs and post your resume.

Back to news